Division of Discovery Science & Technology (Bioengineering)

This division supports the development and demonstration of modular platform technologies (without preference for any disease or application) that manipulate and interface with biology to enable new paradigms of clinical intervention for human health.

Core Program Areas: Biotransducers Cluster

Luisa Russell, Ph.D.

Moria Fisher Bittmann, Ph.D.

Moria Fisher Bittmann, Ph.D.

David Rampulla, Ph.D.

Core Program Areas: Bioengineered Systems Cluster

Michael Wolfson, Ph.D.

Moria Fisher Bittmann, Ph.D.

David Rampulla, Ph.D.

Core Program Areas: Translation and Commercialization Cluster

Collaborations

An important aspect of the Institute’s mission is encouraging collaborations among the institutes and centers at NIH, other federal agencies, and the private sector.

  • Interagency Modeling and Analysis Group (IMAG) – IMAG brings together program officers across federal agencies to communicate, disseminate, and plan collaborative activities and joint initiatives related to computational and analytical modeling and analysis of biomedical, biological, and behavioral systems, see IMAG Research. IMAG also hosts the NIH Population Modeling Scientific Interest Group and the Multi-scale Modeling (MSM) Consortium.
     
  • Synthetic Biology Consortium (SBC) - The SBC is a trans-NIH effort to foster collaborations among researchers and share synthetic biology technologies to address unmet needs in biology and medicine.

Related News

  • Science Highlights ·

    dashboard for design of modular cellular functions
    A change of instructions in a computer program directs the computer to execute a different command. Similarly, synthetic biologists are learning the rules for how to direct the activities of human cells.
  • Grantee News ·

    Understanding the physics of clot contraction could potentially lead to new ways to treat bleeding problems and clotting problems.
  • Grantee News ·

    Sickle cell disease leads to chronic pain, organ failure, and early death in patients worldwide. A team has demonstrated a gene editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This treatment rescued disease symptoms in animal models, enabling long-lasting production of healthy blood cells, and could inspire a therapeutic strategy for SCD.
  • Grantee News ·

    Hydrogels are commonly used inside the body to help in tissue regeneration and drug delivery. However, once inside, they can be challenging to control for optimal use. A team of researchers is developing a new way to manipulate the gel -- by using light.
  • NIBIB in the News ·

    Thinking back to a year ago when terror struck worldwide and the full weight of the Covid-19 pandemic began to set in, NIH quickly mobilized on multiple fronts—one of which was the RADx initiative, with the goal of helping to meet the huge demand for fast, accurate Covid-19 tests. Source: NIH Record.